Navigation Links
Stem cell mobilization therapy appears to be ineffective in repairing damage caused by heart attack

Therapy that involved bone marrow stem cells did not improve cardiac function in patients following a heart attack, according to a study in the March 1 issue of JAMA.

There has been increasing evidence that stem cells contribute to regeneration of cardiac tissue and the development of new blood vessels following a heart attack, thus opening up new prospects for stem-cell based therapies. Granulocyte colony-stimulating factor (G-CSF, a growth-factor protein) induces mobilization of bone marrow stem cells, according to background information in the article.

Dietlind Zohlnhöfer, M.D., of the Technische Universität, Munich, Germany, and colleagues conducted a randomized, double-blind, placebo-controlled study (REVIVAL-2) to assess the value of G-CSF treatment in a large group of patients following a heart attack. The 114 patients, diagnosed with ST-segment elevation acute myocardial infarction (a certain pattern on an electrocardiogram indicating a heart attack), had successful reperfusion (restoration of blood flow) to the heart by percutaneous coronary intervention (procedures such as angioplasty in which a catheter-guided balloon is used to open a narrowed coronary artery) within 12 hours after onset of symptoms. Patients were randomly assigned to receive by injection either a daily dose of 10 µg/kg of G-CSF or placebo (an inactive substance) for 5 days. The patients were treated between February 2004 and February 2005.

Treatment with G-CSF produced a significant mobilization of bone marrow stem cells. The researchers found that this did not alter infarct size (area of damage) or left ventricular function after a heart attack. "Moreover, in contrast to other studies, no increase in the risk of restenosis (narrowing again of an artery after treatment) or major adverse cardiac events was observed with G-CSF treatment," the authors write.

"The REVIVAL-2 trial had a cohort that was larger than all 3 previous trials taken together and had a relatively long follow-up period based on sensitive assessment methods of left ventricular function and infarct size. In conclusion, use of G-CSF therapy to mobilize bone marrow–derived stem cell does not improve left ventricular recovery in patients with acute myocardial infarction after successful mechanical reperfusion," they write.


'"/>

Source:JAMA and Archives Journals


Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to lead upcoming ... term focus on Type 2 diabetes and associated comorbidities. , Justin brings over ... and classes. As Chief Commercial Officer, Justin will lead Better Therapeutics’ ...
(Date:7/18/2020)... TORONTO (PRWEB) , ... July 17, 2020 , ... Commercial ... hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic ... competitive and price pressure is not going away and capturing full value from every ...
(Date:7/4/2020)... ... , ... Aesthetics Biomedical (ABM), a leading aesthetics product development ... the products and treatments developed, but also the dedicated team behind the brands ... built by ABM have received several honors already for 2020, each of which ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and positions ... as MediVet Biologics since its formation in 2016, the company is relaunching itself under ... build on its base of innovative therapies for osteoarthritis and cancer. , ...
(Date:7/31/2020)... ... 29, 2020 , ... Anomet Products has introduced new custom ... use with CRM, neurostimulation, vascular, and related devices. , Anomet Medical Clad ... performance, and cost criteria; especially where solid wire is limited. Typical configurations for ...
(Date:7/31/2020)... ... July 30, 2020 , ... Alucio™, ... announced the release of its signature product called Beacon - a content ... other field medical professionals. , Beacon helps MSLs streamline communication and ...
(Date:7/18/2020)... DAYTON, Ohio (PRWEB) , ... July 16, 2020 ... ... clinical data solutions to aid in the early detection and prevention of high-burden ... partnership to enable US-based hospitals and healthcare organizations to utilize existing data in ...
Breaking Biology Technology: